Shares of Enovis Co. (NYSE:ENOV – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $67.89.
A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Evercore ISI dropped their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC dropped their target price on shares of Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Finally, JMP Securities began coverage on shares of Enovis in a research report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock.
View Our Latest Stock Report on Enovis
Institutional Investors Weigh In On Enovis
Enovis Trading Down 2.6 %
NYSE:ENOV opened at $39.62 on Tuesday. Enovis has a 12 month low of $39.53 and a 12 month high of $65.03. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of -26.41 and a beta of 1.91. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $43.72 and its 200-day moving average is $48.43.
Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The company had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. During the same quarter last year, the firm posted $0.61 earnings per share. The company’s quarterly revenue was up 22.6% compared to the same quarter last year. Equities analysts anticipate that Enovis will post 2.7 EPS for the current year.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Recommended Stories
- Five stocks we like better than Enovis
- Ride Out The Recession With These Dividend Kings
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Best Stocks Under $10.00
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- What is a Bond Market Holiday? How to Invest and Trade
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.